Movetis Announces Start of a Phase IIa trial for M0002 in Ascites
Movetis NV, a Belgian biopharmaceutical company that specializes in developing compounds for gastrointestinal disorders, announced the start of a Phase-IIa multiple-dose trial with one of its lead products, M0002, an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.
The Phase-IIa trial is designed to investigate the efficacy, safety, tolerability and pharmacokinetic profile of M0002 in cirrhotic subjects who experience ascites, an accumulation of fluid in the peritoneal cavity. Conventional diuretic drugs, which are currently used to treat ascites, have the drawback that they promote the excretion of both salt and water, whereas M0002, because it is an electrolyte-sparing aquaretic causes much lower levels of salt excretion. This important differential could potentially offer clinical advantages in the treatment of cirrhosis and other disorders caused by water-retention. In tests conducted to date, single-doses of M0002 (1-5 mg) in patients with liver cirrhosis have resulted in increased output of diluted urine.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Genetically engineering disease-fighting cells
Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown

Bacteria acquire resistance from competitors

Lifestyle-related diseases: clear parallels between humans and bears - Bioinspired approach could offer novel opportunities for the development of medical treatments and drugs for both humans and animals

Liquid cats, disgust for cheese and reversed genitalia - Ig Nobel Prizes awarded
‘Escaped’ proteins add to hearing loss in elderly, UF researchers found
